Efficacy and safety of the SGLT2 inhibitor empagliflozin ver

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c,
whereas linagliptin did not, and might offer a new treatment option for young people
with type 2 diabetes.

Related Keywords

United States , Brussels , Bruxelles Capitale , Belgium , American , , European Association For The Study Of Diabetes , Public Health Nutr , Study Group , American Diabetes Association , International Diabetes Federation , Health Nutr , Englj Med , European Association , American Diabetes ,